Europe Moves To Suspend Merck Cholesterol Drug

Law360, New York (January 18, 2013, 6:55 PM EST) -- The European Medicines Agency announced Friday that it had confirmed a recommendation to suspend a cholesterol drug treatment by Merck Sharp & Dohme Ltd. after concluding that the drug's benefits don't outweigh the risks.

The EMA's Committee for Medicinal Products for Human Use confirmed the recommendation to suspend the marketing authorizations of the drug, a combination of niacin and laropiprant used to treat patients with high levels of triglycerides and cholesterol, a condition known as dyslipidaemia. The drug is sold under the brand names Tredaptive, Pelzont...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.